Castle Biosciences Inc CSTL Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,858

Price:

$76.55
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,142

Price:

$75.80
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,618

Price:

$76.52
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,759

Price:

$75.74
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-611

Price:

$74.56
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,589

Price:

$73.84
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,530

Price:

$72.86
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-270

Price:

$71.66
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-100

Price:

$76.78
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-603

Price:

$74.52

Filings by filing date

Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-611

Price:

$74.56
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,589

Price:

$73.84
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,530

Price:

$72.86
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-270

Price:

$71.66
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-100

Price:

$76.78
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-603

Price:

$74.52
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,118

Price:

$73.96
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,156

Price:

$72.94
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,858

Price:

$76.55
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Maetzold Derek J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,142

Price:

$75.80

News

Biz Brief

Sector: Healthcare	Industry: Medical Equipment, Supplies & Distribution

See Regulatory Filings on SEC

Company Contact

Address:	820 S Friendswood Dr Ste 201 FRIENDSWOOD TX 77546
Tel:	N/A
Website:	www.castlebiosciences.com
IR:	See website

Key People

Daniel Mark Bradbury Independent Chairman of the Board	Bernhard E. Spiess Chief Business Officer	Derek J. Maetzold President, Chief Executive Officer, Founder, Director
Frank Stokes Chief Financial Officer	Toby Juvenal Senior Vice President - Sales	Kristen Oelschlager Senior Vice President - Clinical Operations
Alice Izzo Vice President - Marketing	Bob Cook Vice President - Research & Development	Michael Maltby Executive Director - Managed Care
Noreen Manning Executive Director - Reimbursement

Business Overview

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company. The Company is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company has two market proprietary products, DecisionDx-Melanoma and DecisionDx-UM, and have two active proprietary products in development DecisionDx-UM and DecisionDx-Melanoma. The Company is developing a treatment plan for certain cancers using clinical and pathology factors. Its lead product, DecisionDx-Melanoma, is a proprietary multi-gene expression profile (GEP), a test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer.

Financial Overview

For the nine months ended 30 September 2020, CastleBiosciences Inc revenues increased 32% to $45.4M. Net lossapplicable to common stockholders totaled $5.4M vs. incomeof $936K. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Net loss reflects Dermatological Cancer Companysegment loss totaling $1.3M vs. income of $8.9M, UnitedStates segment loss totaling $645K vs. income of $4.4M.

Employees:	133 as of Dec 31, 2019

Reporting Currency:	U.S. Dollars
Enterprise value:	$1,723M as of Sep 30, 2020
Annual revenue (TTM):	$62.98M as of Sep 30, 2020
EBITDA (TTM):	-$0.49M as of Sep 30, 2020
Net annual income (TTM):	-$3.34M as of Sep 30, 2020
Free cash flow (TTM):	$10.28M as of Sep 30, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	23,844,426 as of Dec 15, 2020
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Castle Biosciences Inc (AR:CSTL)